A

Amgen

Makes biotech medicines for serious illnesses

Manager – Business Operations Partner - Neurology, IgG4-RD

Full-TimeUpdated on 10/24/2026
$109.6k - $148.3k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Mid
Bachelor's, Master's, PhD, Associate's
Remote in USA+2 moreMore locations: California, USA | Deerfield, IL, USA
Remote
Business & StrategyBusiness Operations
H1B Sponsorship Available

About the job

Requirements
  • A doctorate degree, or a master's degree and 2 years of operations, consulting, strategy, business analytics, or commercial experience; or a bachelor's degree and 4 years of such experience; or an associate's degree and 8 years of such experience; or a high school diploma or GED and 10 years of such experience.
Responsibilities
  • Partner with UPLIZNA commercial functions to understand business priorities, operational needs, and interdependencies.
  • Support brand and functional leaders with structured analysis, coordination, and follow-through on agreed priorities.
  • Develop a working knowledge of the UPLIZNA business, customers, market dynamics, and commercial operating environment to inform day-to-day decisions.
  • Proactively identify execution issues, dependencies, and opportunities within assigned areas, and bring forward practical options and recommendations.
  • Build effective working relationships across a complex, matrixed organization and help maintain alignment among project stakeholders.
  • Partner with Business Analytics & Insights, Finance, and cross-functional stakeholders to monitor performance and answer priority business questions.
  • Synthesize performance data, market information, and stakeholder input to identify trends, risks, and opportunities.
  • Conduct structured analyses and scenario assessments, translating findings into actionable recommendations.
  • Develop executive-ready presentations, business reviews, and narratives that make complex information clear and support productive leadership discussions.
  • Establish and track relevant performance measures for assigned initiatives, and recommend actions based on results.
  • Support UPLIZNA planning processes, including brand planning, business reviews, forecasting, Long Range Strategy, and Quarterly Business Reviews.
  • Independently lead defined strategic and/or operational initiatives and special projects or business cases from planning through implementation.
  • Develop project plans with clear deliverables, owners, milestones, risks, dependencies, and measures of success.
  • Coordinate cross-functional working sessions, document decisions, and ensure actions are completed on schedule.
  • Monitor progress, resolve routine execution issues, and escalate material risks or decisions to the appropriate leaders.
  • Manage multiple priorities while maintaining accuracy and follow-through.
  • Serve as the day-to-day project manager for strategic initiatives, coordinating cross-functional work, managing timelines and dependencies, and driving decisions and deliverables to completion.
  • Support effective governance by preparing agendas and materials, maintaining decision and action tracking, and coordinating follow-up.
  • Identify opportunities to use AI, digital capabilities, and automation to improve analysis, planning, communication, and operational efficiency.
Desired Qualifications
  • Experience in Business Operations, Strategy and Operations, Commercial Excellence, Consulting, Analytics, project management, or a related commercial role.
  • Commercial and business acumen, with the ability to connect data and business context to practical recommendations.
  • Experience supporting brand planning, business reviews, forecasting, performance management, governance, or strategic initiatives.
  • Analytical and structured problem-solving skills, including the ability to turn unstructured business questions into clear work plans.
  • Demonstrated project management experience, including ownership of timelines, deliverables, risks, dependencies, and stakeholder alignment.
  • Strong written and verbal communication skills, including experience developing and presenting materials for senior leaders.
  • Ability to synthesize complex information and communicate the implications clearly to different audiences.
  • Ability to collaborate across functions, influence without direct authority, and build trusted relationships in a matrixed organization.
  • Strong organization and prioritization skills, attention to detail, and ability to manage multiple deadlines.
  • Proactive and intellectually curious approach, including identifying problems and recommending solutions.
  • Interest in applying AI, automation, and digital tools to improve business performance and ways of working.
  • Experience in the biopharmaceutical industry, rare disease, or specialty markets.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.